Kotak has upgraded Clear Science to purchase from scale back with the goal value at Rs 1,370 from Rs 1,380 earlier. Analysts really feel the risk-reward ratio is now beneficial for the inventory. The inventory fell over 20% in only a month following the founding household’s 24% stake sale, which is now concluded. Analysts now discover risk-reward extra engaging, contemplating the corporate’s wholesome pipeline of progress tasks. They made modest tweaks to estimates based mostly on incremental disclosures.Nuvama maintained its purchase advice on Aditya Imaginative and prescient with the goal value at Rs 580 from Rs 503 earlier. Analysts mentioned that the corporate, after increase a big AC stock in March, confronted a weak April-June quarter (Q1FY26). To handle extra inventory, AVL halted AC orders after April. The corporate has a robust OEM help. Doubling of demonstrator incentives and dealing capital extension have been essential in clearing stock. And now the upcoming GST cuts are anticipated to enhance demand subsequent season. Analysts really feel with a robust begin to central UP enlargement, per-store throughput is more likely to get better to FY25 ranges by FY27.UBS has a purchase score on TVS Motor with the goal value at Rs 3,475. Analysts mentioned the launch of Orbiter, engaging priced and focusing on the youth, would strengthen its no 1 EV place. In addition they really feel competitors to heat-up within the e2W area with the current launches.Motilal Oswal Securities maintained its purchase advice on Dr Agarwal’s Well being Care with the goal value at Rs 530. Analysts mentioned the proposed merger of Dr Agarwal Eye Hospital and Dr Agarwal Healthcare to drive EPS accretion. The completion of the merger is anticipated in 12-24 months, topic to approvals. They mentioned on a pro-forma foundation, minority curiosity associated to the 28% stake of public shareholding in AEHL can be eradicated.Investec maintained its promote advice on Indigo with the goal value at Rs 4,050, a draw back of about 29%. Analysts mentioned the inventory’s valuations are already pricing in aggressive progress by FY30 whereas earnings momentum is weakening. In addition they really feel any extra provide might weigh on the inventory value.(Disclaimer: The opinions, analyses and proposals expressed herein are these of brokerage and don’t replicate the views of The Occasions of India. At all times seek the advice of with a professional funding advisor or monetary planner earlier than making any funding selections.)